Bullish
$NVTA Per the press release and my conversation with the executive team, we now know that Q4 2019 so the largest additions of bio-pharma partners ever. The momentum is accelerating, as it did for all of 2019. Institutional accounted for ~25% of revenue in Q3. This raises ASPs
  • 11